Tildacerfont

• CAT Number: I037303
• CAS Number: 1014983-00-6
• Molecular Formula: C20H26ClN5OS
• Molecular Weight: 419.97
• Purity: 98%
• Synonyms: Tildacerfont
• Target: CRFR
• Solubility: Soluble in DMSO
• Appearance: Solid powder
• Storage: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
• IUPAC Name: 4-(4-chloro-5-(2,5-dimethyl-7-(pentan-3-yl)pyrazolo[1,5-a]pyrimidin-3-yl)thiazol-2-yl)morpholine
• InChI: InChI=1S/C20H26ClN5OS/c1-5-14(6-2)15-11-12(3)22-19-16(13(4)24-26(15)19)17-18(21)23-20(28-17)25-7-9-27-10-8-25/h11,14H,5-10H2,1-4H3
• InChIKey: XVAWSBAQNIXMIO-UHFFFAOYSA-N
• SMILES: CCC(C1=CC(C)=NC2=C(C3=C(Cl)N=C(N4CCOCC4)S3)C(C)=NN12)CC

Tildacerfont(CAT: I037303) is a potent and selective antagonist of the corticotropin-releasing factor 1 receptor (CRF1), widely utilized in endocrinology and stress-related research. By targeting CRF1, Tildacerfont reduces the overactivation of the hypothalamic-pituitary-adrenal (HPA) axis, which is implicated in conditions such as congenital adrenal hyperplasia (CAH), Cushing’s syndrome, and anxiety disorders. Its high specificity and favorable pharmacokinetic profile make it ideal for in vitro and in vivo studies, providing insights into CRF1 signaling pathways and supporting the development of therapeutic strategies for HPA axis dysregulation and related endocrine disorders.